BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

Stock Information for BioStem Technologies Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioStem Technologies Inc

BioStem Technologies Products Placed on "12-Month Status Quo Period" List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies® to Debut American Amnion(TM) at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
BioStem Technologies Expands Product Access in Medicaid
BioStem Technologies Reports Third Quarter 2025 Financial Results
BioStem Technologies Announces Filing of Restated Financial Statements
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters
BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.